Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
1 clinical trials · Condition
◉ Watch Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma (NCT02244489) | Sierra Oncology LLC - a GSK company | 2014-11-05 |
Track Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.